DMAC (DiaMedica Therapeutics) Days Payable: 0.00 (As of Mar. 2026)

What is DiaMedica Therapeutics Days Payable?

DiaMedica Therapeutics DMAC +1.75% 31 Days Payable is 0.00 as of Mar. 2026. GuruFocus rates DMAC with a GF Score™ of 31/100. The stock has 1 warning sign investors should review. Among 708 Biotechnology companies, DiaMedica Therapeutics ranks worse than 141242.8% on this metric.

DiaMedica Therapeutics's average Accounts Payable for the three months ended in Mar. 2026 was $2.38 Mil. DiaMedica Therapeutics's Cost of Goods Sold for the three months ended in Mar. 2026 was $0.00 Mil.

The historical rank and industry rank for DiaMedica Therapeutics's Days Payable or its related term are showing as below:

DMAC's Days Payable is not ranked ^*
in the Biotechnology industry.
Industry Median: 113.56
* Ranked among companies with meaningful Days Payable only.

DiaMedica Therapeutics's Days Payable stayed the same from Mar. 2025 (0.00) to Mar. 2026 (0.00). stayed the same

DiaMedica Therapeutics Days Payable Related Terms

DiaMedica Therapeutics Days Payable Historical Data

* Premium members only.

The historical data trend for DiaMedica Therapeutics's Days Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

DiaMedica Therapeutics Days Payable Chart

DiaMedica Therapeutics Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

Days Payable

Get a 7-Day Free Trial

0.00

DiaMedica Therapeutics Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
Days Payable	Get a 7-Day Free Trial															0.00	0.00	0.00	0.00	0.00

DMAC vs BCYC, RZLT, ABEO: Days Payable Comparison

For the Biotechnology subindustry, DiaMedica Therapeutics's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

DiaMedica Therapeutics Days Payable vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, DiaMedica Therapeutics's Days Payable distribution charts can be found below:

* The bar in red indicates where DiaMedica Therapeutics's Days Payable falls into.

Save Embed

31GF Score

DiaMedica Therapeutics Inc DMAC

Days Payable is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

DiaMedica Therapeutics Days Payable Calculation

Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.

DiaMedica Therapeutics's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as

	Days Payable (A: Dec. 2025 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (A: Dec. 2024 )	+	Accounts Payable (A: Dec. 2025 ))	/	count )	/	Cost of Goods Sold (A: Dec. 2025 )	*	Days in Period
=	( (0.94	+	1.475)	/	2 )	/	0	*	365
=	1.2075					/	0	*	365
=	N/A

DiaMedica Therapeutics's Days Payable for the quarter that ended in Mar. 2026 is calculated as:

	Days Payable (Q: Mar. 2026 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (Q: Dec. 2025 )	+	Accounts Payable (Q: Mar. 2026 ))	/	count )	/	Cost of Goods Sold (Q: Mar. 2026 )	*	Days in Period
=	( (1.475	+	3.293)	/	2 )	/	0	*	365 / 4
=	2.384					/	0	*	365 / 4
=	N/A

Frequently Asked Questions Learn more about Days Payable →

What does a Days Payable of 0.00 mean?

DiaMedica Therapeutics (DMAC) has a Days Payable of 0.00 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on DiaMedica Therapeutics and its competitors. According to the industry distribution chart, DiaMedica Therapeutics ranks #999999 out of 708 companies in the Biotechnology industry.

Is DiaMedica Therapeutics' Days Payable too high?

DiaMedica Therapeutics' current Days Payable is 0.00. Based on the distribution chart, DiaMedica Therapeutics ranks #999999 out of 708 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, DiaMedica Therapeutics has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.

How does DiaMedica Therapeutics' Days Payable compare to BCYC and RZLT?

According to the Biotechnology industry distribution chart, DiaMedica Therapeutics ranks #999999 out of 708 companies for Days Payable. This places DiaMedica Therapeutics in the lower half of its industry. The industry median Days Payable is 113.56. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good Days Payable for a Biotechnology company?

The median Days Payable among Biotechnology companies is 113.56, based on 708 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high Days Payable mean?

A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on DiaMedica Therapeutics and its competitors. For the Biotechnology industry, the median Days Payable is 113.56 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. DiaMedica Therapeutics's current Days Payable is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is DiaMedica Therapeutics stock overvalued right now?

DiaMedica Therapeutics (DMAC) has a current Days Payable of 0.00. The current Days Payable is 0.00. DiaMedica Therapeutics' overall GF Score™ is 31/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is Days Payable calculated?

Days Payable is calculated from a company's financial statements. For DiaMedica Therapeutics (DMAC), the current Days Payable is 0.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

DiaMedica Therapeutics Business Description

Industry Healthcare Biotechnology

Comparable Companies BCYC RZLT ABEO FATE LCTX TENX RCKT IVVD PRLD NAGE VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY RVMD ASX:CSL ONC XKRX:068270

Address 301 Carlson Parkway, Suite 210, Minneapolis, MN, USA, 55305

Website https://www.diamedica.com

DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.

31GF Score

Get the complete analysis for DMAC

Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$6.36

Price

View DMAC Analysis

See Days Payable data for all stocks →